Leerink Partnrs Issues Optimistic Forecast for AQST Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($0.47) per share for the year, up from their prior estimate of ($0.50). The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics' Q4 2024 earnings at ($0.14) EPS.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analysts' expectations of $12.69 million. During the same period in the prior year, the company earned ($0.03) EPS.

AQST has been the topic of several other research reports. Leerink Partners increased their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. JMP Securities restated a "market outperform" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of "Buy" and an average target price of $8.83.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST traded up $0.38 during midday trading on Friday, reaching $5.46. 1,741,806 shares of the stock traded hands, compared to its average volume of 1,753,536. The company's 50 day moving average is $4.94 and its 200 day moving average is $3.85. Aquestive Therapeutics has a one year low of $1.55 and a one year high of $6.23. The stock has a market capitalization of $497.19 million, a PE ratio of -12.13 and a beta of 2.82.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AQST. Janney Montgomery Scott LLC purchased a new stake in Aquestive Therapeutics in the first quarter worth $1,456,000. SG Americas Securities LLC bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth $54,000. Vanguard Group Inc. grew its position in shares of Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company's stock worth $13,813,000 after buying an additional 1,353,518 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company's stock worth $124,000 after buying an additional 15,601 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of Aquestive Therapeutics by 219.7% during the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company's stock worth $438,000 after buying an additional 70,666 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.